

Payal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4425512/publications.pdf>

Version: 2024-02-01

127
papers

6,186
citations

126907

33
h-index

79698

73
g-index

130
all docs

130
docs citations

130
times ranked

9596
citing authors

#	ARTICLE	IF	CITATIONS
1	BAP1 loss defines a new class of renal cell carcinoma. <i>Nature Genetics</i> , 2012, 44, 751-759.	21.4	791
2	Targeting renal cell carcinoma with a HIF-2 antagonist. <i>Nature</i> , 2016, 539, 112-117.	27.8	521
3	Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. <i>Lancet Oncology</i> , The, 2013, 14, 159-167.	10.7	383
4	Spectrum of diverse genomic alterations define non-“clear cell renal carcinoma subtypes. <i>Nature Genetics</i> , 2015, 47, 13-21.	21.4	310
5	A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer. <i>Cell</i> , 2013, 154, 1074-1084.	28.9	257
6	Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo. <i>Cell Metabolism</i> , 2018, 28, 793-800.e2.	16.2	193
7	A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma. <i>Science Translational Medicine</i> , 2012, 4, 137ra75.	12.4	159
8	SCINA: Semi-Supervised Analysis of Single Cells in Silico. <i>Genes</i> , 2019, 10, 531.	2.4	150
9	An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors. <i>Cancer Discovery</i> , 2018, 8, 1142-1155.	9.4	138
10	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1392-1424.	5.5	138
11	Modeling Renal Cell Carcinoma in Mice: <i>Bap1</i> and <i>Pbrm1</i> Inactivation Drive Tumor Grade. <i>Cancer Discovery</i> , 2017, 7, 900-917.	9.4	128
12	<i>Bap1</i> is essential for kidney function and cooperates with <i>Vhl</i> in renal tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 16538-16543.	7.1	123
13	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1167-1184.	5.5	118
14	HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 793-803.	7.0	117
15	Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis. <i>Modern Pathology</i> , 2005, 18, 197-204.	5.5	113
16	Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. <i>Journal of Urology</i> , 2016, 195, 180-187.	0.4	113
17	A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma. <i>Nature Communications</i> , 2015, 6, 8699.	12.8	99
18	Interplay Between pVHL and mTORC1 Pathways in Clear-Cell Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2011, 9, 1255-1265.	3.4	97

#	ARTICLE	IF	CITATIONS
19	A patientâ€derived explant (<sc>PDE</sc>) model of hormoneâ€dependent cancer. <i>Molecular Oncology</i> , 2018, 12, 1608-1622.	4.6	94
20	Oncometabolites: A New Paradigm for Oncology, Metabolism, and the Clinical Laboratory. <i>Clinical Chemistry</i> , 2017, 63, 1812-1820.	3.2	77
21	BAP1 Immunohistochemistry Predicts Outcomes in a Multi-Institutional Cohort with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 603-610.	0.4	69
22	Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer. <i>Cell Reports</i> , 2016, 17, 2620-2631.	6.4	68
23	IFN γ -Induced IFIT5 Promotes Epithelial-to-Mesenchymal Transition in Prostate Cancer via miRNA Processing. <i>Cancer Research</i> , 2019, 79, 1098-1112.	0.9	63
24	Unsaturated Fatty Acids Stimulate Tumor Growth through Stabilization of β -Catenin. <i>Cell Reports</i> , 2015, 13, 495-503.	6.4	57
25	Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. <i>Modern Pathology</i> , 2016, 29, 34-42.	5.5	55
26	PD-L1 detection using ^{89}Zr -atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response. , 2019, 7, 144.		53
27	Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection. <i>European Urology</i> , 2020, 77, 290-292.	1.9	48
28	Fatty acid synthase expression in cutaneous melanocytic neoplasms. <i>Modern Pathology</i> , 2005, 18, 1107-1112.	5.5	46
29	Tumor Vascularity in Renal Masses: Correlation of Arterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e25-e36.	1.9	44
30	Radiomics in Kidney Cancer. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2019, 27, 1-13.	1.1	41
31	Loss of PBRM1 and BAP1 expression is less common in nonâ€clear cell renal cell carcinoma than in clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 23.e9-23.e14.	1.6	40
32	Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 981-988.	1.6	39
33	Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombusâ€Safety Lead-in Results of a Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1135-1142.	0.8	36
34	Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 645-645.	1.6	36
35	Prospective Analysis of Ki-67 as an Independent Predictor of Oncologic Outcomes in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2014, 191, 28-34.	0.4	35
36	Novel MEIS1-NCOA2 Gene Fusions Define a Distinct Primitive Spindle Cell Sarcoma of the Kidney. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1562-1570.	3.7	35

#	ARTICLE	IF	CITATIONS
37	Prospective performance of clear cell likelihood scores (ccLS) in renal masses evaluated with multiparametric magnetic resonance imaging. <i>European Radiology</i> , 2021, 31, 314-324.	4.5	35
38	Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3706-3713.	1.6	34
39	Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney. <i>Modern Pathology</i> , 2022, 35, 333-343.	5.5	34
40	Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase. <i>Oncogene</i> , 2019, 38, 5580-5598.	5.9	33
41	Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type. <i>EBioMedicine</i> , 2020, 51, 102526.	6.1	33
42	Development of a Patient-specific Tumor Mold Using Magnetic Resonance Imaging and 3-Dimensional Printing Technology for Targeted Tissue Procurement and Radiomics Analysis of Renal Masses. <i>Urology</i> , 2018, 112, 209-214.	1.0	32
43	Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: Results of a current series and a review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 54.e19-54.e26.	1.6	31
44	Intratumor Heterogeneity of Perfusion and Diffusion in Clear-Cell Renal Cell Carcinoma: Correlation With Tumor Cellularity. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e585-e594.	1.9	31
45	Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation. <i>Nucleic Acids Research</i> , 2019, 47, 11623-11636.	14.5	30
46	Prospective Comparison of Molecular Signatures in Urothelial Cancer of the Bladder and the Upper Urinary Tract—Is There Evidence for Discordant Biology?. <i>Journal of Urology</i> , 2014, 191, 926-931.	0.4	29
47	SPARC is a key mediator of TGF β -induced renal cancer metastasis. <i>Journal of Cellular Physiology</i> , 2021, 236, 1926-1938.	4.1	29
48	Epigenetic silencing of the ubiquitin ligase subunit FBXL7 impairs c-SRC degradation and promotes epithelial-to-mesenchymal transition and metastasis. <i>Nature Cell Biology</i> , 2020, 22, 1130-1142.	10.3	28
49	Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management. <i>Journal of Urology</i> , 2021, 205, 137-144.	0.4	28
50	High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma. <i>Oncotarget</i> , 2015, 6, 16951-16962.	1.8	28
51	Primary Mucinous Adenocarcinoma of the Thymus: A Case Report and Review of the Literature. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 201-204.	2.5	28
52	BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor. <i>BMC Urology</i> , 2017, 17, 19.	1.4	26
53	Eosinophilic Vacuolated Tumor of the Kidney: A Review of Evolving Concepts in This Novel Subtype With Additional Insights From a Case With MTOR Mutation and Concomitant Chromosome 1 Loss. <i>Advances in Anatomic Pathology</i> , 2021, 28, 251-257.	4.3	26
54	Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection. <i>European Urology Open Science</i> , 2021, 26, 83-87.	0.4	26

#	ARTICLE	IF	CITATIONS
55	Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer. <i>International Journal of Cancer</i> , 2017, 141, 2121-2130.	5.1	25
56	Determinants of renal cell carcinoma invasion and metastatic competence. <i>Nature Communications</i> , 2021, 12, 5760.	12.8	25
57	Lymphovascular invasion in clear cell renal cell carcinoma—Association with disease-free and cancer-specific survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 30.e23-30.e28.	1.6	24
58	Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15-year experience and lessons learned. <i>BMC Urology</i> , 2016, 16, 43.	1.4	24
59	Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma. , 2020, 8, e001198.		24
60	The Evolution of Angiogenic and Inflamed Tumors: The Renal Cancer Paradigm. <i>Cancer Cell</i> , 2020, 38, 771-773.	16.8	23
61	Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis. <i>Oncotarget</i> , 2015, 6, 18038-18049.	1.8	23
62	Dysregulation of β -Catenin is an Independent Predictor of Oncologic Outcomes in Patients with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 1671-1677.	0.4	22
63	Low Testosterone Levels Result in Decreased Periurethral Vascularity via an Androgen Receptor-mediated Process: Pilot Study in Urethral Stricture Tissue. <i>Urology</i> , 2017, 105, 175-180.	1.0	22
64	Magnetic Resonance Imaging Radiomics Analyses for Prediction of High-Grade Histology and Necrosis in Clear Cell Renal Cell Carcinoma: Preliminary Experience. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 12-21.e1.	1.9	22
65	Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 31508-31519.	1.8	22
66	Primary Adenocarcinoma of the Urinary Bladder. <i>American Journal of Clinical Pathology</i> , 2011, 135, 822-830.	0.7	21
67	What is the role of nephrectomy following complete response to checkpoint inhibitors?. <i>Urology Case Reports</i> , 2018, 18, 60-63.	0.3	20
68	Prostate cancer detection using combined auto-fluorescence and light reflectance spectroscopy: ex vivo study of human prostates. <i>Biomedical Optics Express</i> , 2014, 5, 1512.	2.9	19
69	Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 485.e7-485.e14.	1.6	19
70	Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation. <i>Clinical Cancer Research</i> , 2019, 25, 4542-4551.	7.0	19
71	Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2014, 84, 1134-1140.	1.0	18
72	PBRM1 loss is a late event during the development of cholangiocarcinoma. <i>Histopathology</i> , 2017, 71, 375-382.	2.9	18

#	ARTICLE	IF	CITATIONS
73	Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform. <i>Clinical Cancer Research</i> , 2021, 27, 4794-4806.	7.0	17
74	Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. <i>Urology</i> , 2016, 94, 314.e1-314.e7.	1.0	16
75	A renal cell carcinoma tumorgraft platform to advance precision medicine. <i>Cell Reports</i> , 2021, 37, 110055.	6.4	16
76	Utility of Biomarkers in the Prediction of Oncologic Outcome after Radical Cystectomy for Squamous Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 451-456.	0.4	15
77	Current Challenges in Diagnosis and Assessment of the Response of Locally Advanced and Metastatic Renal Cell Carcinoma. <i>Radiographics</i> , 2019, 39, 998-1016.	3.3	14
78	Light Reflectance Spectroscopy to Detect Positive Surgical Margins on Prostate Cancer Specimens. <i>Journal of Urology</i> , 2016, 195, 479-484.	0.4	13
79	EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1079-1089.	4.1	13
80	Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 6716-6725.	7.0	12
81	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839.	7.0	12
82	Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 478-484.	1.6	11
83	Sclerosing lobular hyperplasia of breast: cytomorphic and histomorphic features: a case report. <i>CytoJournal</i> , 2006, 3, 8.	1.7	10
84	Pathologic Quiz Case: Paratesticular Mass in a Young Man. <i>Archives of Pathology and Laboratory Medicine</i> , 2004, 128, 589-590.	2.5	10
85	Renal Cell Carcinoma Pseudoprogression with Clinical Deterioration: To Hospice and Back. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 485-488.	1.9	9
86	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2019, 37, 2419-2427.	2.2	9
87	Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2021, , .	1.9	9
88	Vulvar Fibroadenoma with Lactational Changes in Ectopic Breast Tissue. <i>Case Reports in Obstetrics and Gynecology</i> , 2013, 2013, 1-4.	0.3	8
89	Role of fibroblast growth factor in squamous cell carcinoma of the bladder: Prognostic biomarker and potential therapeutic target. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 111.e1-111.e7.	1.6	8
90	Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: Preliminary results. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 18.e21-18.e26.	1.6	8

#	ARTICLE	IF	CITATIONS
91	Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study. <i>Bladder Cancer</i> , 2016, 2, 91-99.	0.4	8
92	Detecting positive surgical margins: utilisation of light reflectance spectroscopy on <i>ex vivo</i> prostate specimens. <i>BJU International</i> , 2016, 118, 885-889.	2.5	8
93	Statistical clustering of parametric maps from dynamic contrast enhanced MRI and an associated decision tree model for non-invasive tumour grading of T1b solid clear cell renal cell carcinoma. <i>European Radiology</i> , 2018, 28, 124-132.	4.5	8
94	Metastatic "Burned Out" Seminoma Causing Neurological Paraneoplastic Syndrome" Not Quite "Burned Out". <i>Frontiers in Neurology</i> , 2018, 9, 20.	2.4	8
95	The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC. <i>Clinical and Translational Medicine</i> , 2022, 12, e695.	4.0	8
96	Pretreatment biopsy analysis of DAB 2 IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapy. <i>Cancer Medicine</i> , 2015, 4, 1844-1852.	2.8	7
97	Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?. <i>World Journal of Urology</i> , 2016, 34, 105-112.	2.2	7
98	Improving Renal Tumor Biopsy Prognostication With BAP1 Analyses. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 154-165.	2.5	7
99	Tailoring treatment of rectal adenocarcinoma. <i>Anti-Cancer Drugs</i> , 2011, 22, 362-370.	1.4	6
100	Immunohistochemical Expression of Neural Cell Adhesion Molecule in Wilms Tumors, Nephrogenic Rests, and Fetal and Postnatal Renal Cortices. <i>Pediatric and Developmental Pathology</i> , 2011, 14, 16-19.	1.0	6
101	DOC-2/DAB2 Interacting Protein Status in High-Risk Prostate Cancer Correlates With Outcome for Patients Treated With Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 729-735.	0.8	6
102	PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 496-505.	1.6	6
103	The spectrum of renal cell carcinoma in adults. <i>Abdominal Radiology</i> , 2016, 41, 1052-1065.	2.1	5
104	Renal Cell Carcinoma With Pulmonary Metastasis and Metachronous Non-Small Cell Lung Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e675-e680.	1.9	5
105	What morphology can teach us about renal cell carcinoma clonal evolution. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2020, 18, 68-76.	0.1	5
106	Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 343.e1-343.e8.	1.6	4
107	A Review Leveraging a Rare and Unusual Case of Basal Cell Carcinoma of the Prostate. <i>Case Reports in Pathology</i> , 2021, 2021, 1-8.	0.3	4
108	Grade progression in urothelial carcinoma can occur with high or low mutational homology: a first-step toward tumor-specific care in initial low-grade bladder cancer. <i>Oncotarget</i> , 2018, 9, 9415-9424.	1.8	4

#	ARTICLE	IF	CITATIONS
109	Predictive capacity of miRNA-375 in identifying teratoma in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND).. Journal of Clinical Oncology, 2020, 38, 416-416.	1.6	4
110	Safety and efficacy of immune checkpoint inhibitors (ICI) in metastatic non-clear cell renal cell carcinoma (nccRCC): An institutional experience.. Journal of Clinical Oncology, 2020, 38, 640-640.	1.6	3
111	Pathologic Quiz Case: Myxoid Tibial Lesion in a 31-Year-Old Man. Archives of Pathology and Laboratory Medicine, 2004, 128, e65-e66.	2.5	3
112	Real-world application of pre-orchietomy miR-371a-3p test in testicular germ cell tumor (GCT) management.. Journal of Clinical Oncology, 2021, 39, 387-387.	1.6	2
113	Predictive Biomarkers for Response to Therapy in Advanced Colorectal/Rectal Adenocarcinoma. Critical Reviews in Oncogenesis, 2012, 17, 361-372.	0.4	2
114	Pathologic Quiz Case: Laryngeal Lesion in an Elderly Man. Archives of Pathology and Laboratory Medicine, 2005, 129, 115-116.	2.5	2
115	Discriminative Spectral Pattern Analysis for Positive Margin Detection of Prostate Cancer Specimens using Light Reflectance Spectroscopy. IJSE Transactions on Healthcare Systems Engineering, 2018, 8, 144-154.	1.7	1
116	Improved imaging-pathology correlation with MR imaging-derived, 3D-printed, patient-specific whole-mount molds of the prostate.. Journal of Clinical Oncology, 2017, 35, 44-44.	1.6	1
117	Comprehensive molecular and genomic characterization of pancreatic tropism in metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2019, 37, 633-633.	1.6	1
118	Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative magnetic resonance imaging.. Journal of Clinical Oncology, 2017, 35, 460-460.	1.6	1
119	Unraveling the molecular profile underpinning pancreatic tropisms in metastatic clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2019, 37, e16096-e16096.	1.6	1
120	Basic Histopathologic Assessment of Germ Cell Tumors for Clinic and Research. Methods in Molecular Biology, 2021, 2195, 1-11.	0.9	1
121	Serum microRNA-371a-3p levels to predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection.. Journal of Clinical Oncology, 2020, 38, 417-417.	1.6	1
122	Assessment of intratumor heterogeneity using imaging texture features in clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2019, 37, 663-663.	1.6	0
123	Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.. Journal of Clinical Oncology, 2019, 37, 651-651.	1.6	0
124	The role of architectural patterns and cytologic features in the prognosis of clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2019, 37, 632-632.	1.6	0
125	Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.. Journal of Clinical Oncology, 2019, 37, e16100-e16100.	1.6	0
126	Dynamic contrast-enhanced MRI to predict intratumoral molecular heterogeneity in clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2019, 37, 4580-4580.	1.6	0

#	ARTICLE	IF	CITATIONS
127	A real-world experience of immune checkpoint inhibitors (ICI) in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2020, 38, 647-647.	1.6	0